INTRODUCTION
The CNS comprises many different pluripotent and differentiated cell types that vary greatly in abundance during human lifespan. This is reflected by a broad diversity of CNS tumor entities, some of which are relatively common, whereas others develop rarely, and many of them occur at defined ages. Primitive neuroectodermal tumors of the CNS (CNS-PNETs) are highly malignant neoplasms that predominantly affect children but may also arise in adolescents and adults. Histologically, CNS-PNETs are characterized by small, poorly differentiated or undifferentiated embryonal cells with a propensity for both glial and neuronal differentiation (Louis et al., 2007) , but the neuropathological diagnosis is challenging due to a lack of defining molecular markers and histological overlap with other high-grade neuroepithelial tumors. The original concept related medulloblastoma (i.e., PNET of the cerebellum) to embryonal tumors of the cerebrum (supratentorial PNET) (Rorke, 1983) , but issues with the clinicopathological utility of classifying non-cerebellar CNS-PNETs have generated significant controversy over decades (Rorke et al., 1997) . This resulted in considerable uncertainty regarding accurate diagnosis and optimal treatment for affected patients (Jakacki et al., 2015) . The 2007 World Health Organization (WHO) classification of CNS tumors lists CNS-PNET NOS (not otherwise specified) and four histological CNS-PNET variants distinguished by morphological features: CNS neuroblastoma, CNS ganglioneuroblastoma, medulloepithelioma (ME), and ependymoblastoma (EB) (Louis et al., 2007) . Embryonal tumors with abundant neuropil and true rosettes (ETANTR) have been recognized as a histological variant without a specific designation. The identification of focal amplification of a micro-RNA cluster on 19q13.42 (C19MC) as a unifying feature of ME, EB, and ETANTR (Eberhart et al., 2000; Korshunov et al., 2010 Korshunov et al., , 2014 Li et al., 2009; Spence et al., 2014) led to the recognition of an overarching molecular and clinicopathological entity of embryonal tumors with multi-layered rosettes (ETMR, in the next revision of the WHO classification, adding to a growing list of defining molecular aberrations in high-grade pediatric CNS tumors (Capper et al., 2010; Chan et al., 2013; Hasselblatt et al., 2013; Margol and Judkins, 2014; Pajtler et al., 2015; Parker et al., 2014; Schneppenheim et al., 2010; Schwartzentruber et al., 2012; Venneti et al., 2013; Wu et al., 2012; Yan et al., 2009) .
Recent studies support the notion that CNS-PNETs represent a molecularly heterogeneous group of tumors (Danielsson et al., 2015; Picard et al., 2012; Schwalbe et al., 2013) , indicating an urgent need for better methods of classification. To provide a better framework for accurate diagnosis and treatment, we performed a comprehensive molecular characterization of a large cohort of institutionally diagnosed CNS-PNETs, aiming to fully elucidate their underlying molecular and biological spectrum.
RESULTS

DNA Methylation Profiling of CNS-PNETs
We generated genome-wide DNA methylation profiles of 323 tumors with an institutional diagnosis of ''CNS-PNET.'' Unsupervised clustering, including 211 well-characterized ''reference'' tumors representing other CNS tumor entities, reliably separated samples into clusters defined by histological entities and known molecular subgroups ( Figures 1A, 1B , and S1A-S1D; Table S1 ). 1C , S1A, and S1B). Some CNS-PNETs also grouped with medulloblastoma subtypes (MB WNT , MB SHH , MB Grp3 , MB Grp4 , 11/323, 3%), including one metastasis of a primary brainstem lesion with PNET histology. However, available radiological reports of these MB-like cases did not indicate a cerebellar lesion. Three further samples (1%) clustered with non-neoplastic hemispheric brain tissue samples, suggesting high normal cell content. (B) 2D representation of pairwise sample correlations using the 10,000 most variably methylated probes by t-distributed stochastic neighbor embedding (tSNE) dimensionality reduction. The same samples as in (A) are used (n = 534). Reference samples are colored according to their molecular reference entity. CNS-PNET samples are colored in black. Lines connect each sample to the centroid of its respective molecular CNS tumor entity. (C) Re-classification of 323 CNS-PNETs into known molecular reference entities and four new CNS tumor entities by molecular profiling. Entities correspond to DNA methylation clusters and are represented by colors as indicated. See also Figure S1 and Table S1 .
Some of the remaining CNS-PNETs (50/323, 15%) formed small, inhomogeneous clusters (<5 tumors) or represented distant outliers that failed to group with each other or any of the reference tumor entities, possibly representing exceedingly rare entities. A larger fraction of remaining CNS-PNETs (77/ 323, 24%) formed four separate clusters clearly distinct from reference entities. As elucidated below, these represent four new CNS tumor entities that we termed ''CNS neuroblastoma with FOXR2 activation'' (CNS NB-FOXR2; 44/323, 14%), ''CNS Ewing sarcoma family tumor with CIC alteration'' (CNS EFT-CIC; 12/323, 4%), ''CNS high-grade neuroepithelial tumor with MN1 alteration'' (CNS HGNET-MN1; 11/323, 3%), and ''CNS high-grade neuroepithelial tumor with BCOR alteration'' (CNS HGNET-BCOR; 10/323, 3%). Unsupervised clustering restricted to CNS-PNET samples recapitulated cluster associations established in the overall analysis (Figures S1C and S1E). For a subset of tumors (109 reference samples; 59 CNS-PNET), transcriptomic profiling allowed assignment into gene expression-based subgroups that correlated well with DNA methylation clusters ( Figures 1A, S1A , and S1F).
Re-classification of CNS-PNETs into Other CNS Tumor Entities
To validate the re-classification of CNS-PNETs sharing concordant DNA methylation and transcriptomic profiles with reference tumor entities, we analyzed these samples for hallmark molecular features previously established for their assigned reference tumor entities. Only CNS-PNET samples from the ETMR cluster consistently harbored the C19MC amplicon (33/36, 92% of samples with available data; p < 0.001) and displayed high LIN28A protein expression (17/17, 100%; p < 0.001), which has been proposed as a potent diagnostic marker for ETMR (Korshunov et al., , 2014 Spence et al., 2014) (Figure 2A ). All analyzed CNS-PNET samples from the AT/RT cluster displayed SMARCB1 mutations and/or deletions (14/14, 100%; p < 0.001) and loss of the SMARCB1 protein product INI-1 (5/5, 100%; p < 0.001) ( Figure 2B ). Targeted sequencing confirmed mutations in IDH1 in 15/15 CNS-PNETs (100%; p < 0.001) from the HGG IDH cluster, G34 mutations of H3F3A in 17/17 CNS-PNETs (100%; p < 0.001) from the HGG G34 cluster, and K27 mutations of H3F3A in 4/7 CNS-PNETs (57%; p < 0.001) from the HGG K27 cluster ( Figure 2C ). Within the HGG MYCN cluster, 20/28 CNSPNETs (71%; p < 0.001) displayed amplification of the MYCN locus ( Figure 2D ). Co-amplification of MYCN and ID2 was observed in 12/28 (43%; p < 0.001) samples, therefore broadening a previously defined molecular subgroup of diffuse intrinsic pontine gliomas (DIPG) to include supratentorial tumors with HGG or PNET histopathology (Buczkowicz et al., 2014) . Where tested by fluorescence in situ hybridization (FISH; 4/4), MYCN and ID2 were co-amplified in the same tumor cell nuclei ( Figure 2D ). CNSPNETs within the HGG RTK clusters showed diverse, broad chromosomal copy-number alterations, and half (14/28, 50%) harbored focal amplifications and/or deletions of known oncogenes and/or tumor suppressor genes ( Figures S2A and S2B ). In the three CNS-PNETs from the EWS cluster, the presence of a EWSR1 re-arrangement was detected by RNA sequencing or FISH analysis (data not shown). There was insufficient material to investigate CNS-PNETs from the EPN clusters for the presence of RELA or YAP1 fusions. Patient information (age at diagnosis, tumor location, and survival) of CNS-PNETs from aforementioned clusters matched clinical features of their reference entities and subgroups .
Where available, the histology of CNS-PNETs with DNA methylation profiles and molecular markers associated with other CNS tumor entities (n = 71) was re-evaluated by an expert panel of neuropathologists. In most instances, the tumors demonstrated histological features either supporting their molecular re-classification or ambiguous histology for which the entity suggested by the molecular re-classification would be included in the differential diagnosis (Tables S2A-S2C ). Among the tumors re-classified into other CNS tumor entities were small-cell tumors displaying classic features attributed to CNS-PNET ( Figures S2H-S2M ). These features were not restricted to the ETMR group but were also prominent in the HGG G34 and HGG MYCN groups, in which specific examples demonstrated hallmark features of anaplasia, including cell wrapping and prominent nucleoli, while other tumors demonstrated diffuse infiltrative growth more typical of HGG. Rare examples of tumors re-classified into a HGG group demonstrated robust neuronal antigen expression, highlighting the insufficiency of glial and neuronal antigen expression alone to reliably discriminate these malignant small-cell CNS tumors ( Figures S2N-S2P ).
Identification of Four New Molecular CNS Tumor Entities
Our initial clustering analysis of CNS-PNETs identified four new molecular entities designated ''CNS NB-FOXR2,'' ''CNS EFT-CIC,'' ''CNS HGNET-MN1,'' and ''CNS HGNET-BCOR.'' To explore whether these molecular entities were also diagnosed other than CNS-PNET, we compared DNA methylation patterns of each entity with an in-house collection of >10,000 profiles from a broad variety of pediatric and adult CNS tumors (data not shown). Subsequent clustering analysis identified 59 tumors with diverse histological diagnoses that now grouped with one of the four new CNS tumor entities ( Figures 3A, 3B , and S3A-S3C; Table S3 ). While the enlarged CNS NB-FOXR2 (n = 46) and CNS EFT-CIC (n = 15) clusters represented entities with almost exclusive CNS-PNET histology ( Figures 3A and 3B ), the CNS HGNET-MN1 cluster (n = 41) included 16 tumors histologically diagnosed as astroblastoma (ABM)-rare WHOdefined glial tumors-supporting the concept that they are distinct from conventional diffuse glial neoplasms (Louis et al., 2007) . The CNS HGNET-BCOR cluster (n = 34) was expanded by a variety of CNS tumor histologies. Again, molecular subgroup assignment by transcriptomic profiling recapitulated DNA methylation-based clusters ( Figures 3A and S3A ) and allowed the identification of three additional tumors included in further gene expression analyses.
We correlated each of the four novel CNS tumor entities with available basic clinical parameters ( Figures 3C-3F ). Noticeably, the gender ratio was strongly shifted toward females in the CNS HGNET-MN1 (p < 0.001), as also observed for ABM (Louis et al., 2007) . Patient age at diagnosis in CNS HGNET-MN1 was higher compared with other entities (p < 0.001). There were no clear differences in tumor site of occurrence, although occasional cerebellar location was restricted to tumors of the CNS HGNET-MN1 and CNS HGNET-BCOR entities. Infratentorial, non-cerebellar location was not associated with a specific molecular CNS tumor entity. Surgical and pathological reports of four CNS EFT-CIC tumors did not indicate meningeal or osseous origin. Available survival data suggested differences between the novel CNS tumor entities, with significantly better overall survival observed for patients from the CNS HGNET-MN1 compared to the CNS HGNET-BCOR entity ( Figure S3D ).
Histopathology of New CNS Tumor Entities
Histopathological review was performed on 30 CNS NB-FOXR2, 14 CNS HGNET-BCOR, 10 CNS HGNET-MN1, and four CNS EFT-CIC tumors (Tables S2A-S2C ). The CNS NB-FOXR2 entity displayed embryonal architectural and cytological features with a small-cell phenotype ( Figures 4A-4C ). Areas of differentiation in the form of neuropil, neurocytic cells, or ganglion cells were observed in a high proportion of tumors ( Figure 4C ). Frequent perivascular anuclear zones (''vascular pseudorosettes''), nuclear palisades, and Homer Wright rosettes were encountered in individual samples ( Figure S4A ; Tables S2B and S2C ). This group encompassed tumors that would be classified as CNS neuroblastoma or CNS ganglioneuroblastoma in the 2007 WHO classification scheme (Louis et al., 2007) (Figures 4A-4C ). CNS NB-FOXR2 tumors nearly uniformly expressed OLIG2 and the neuronal antigen synaptophysin (Figures S4A and S4B) . Figure S2 and Table S2 .
The CNS EFT-CIC entity was also characterized by a smallcell phenotype but with variable histology (Figures 4D-4F ). The tumor architecture included both alveolar and fascicular patterns of growth. Although tumors were uniformly high grade, this group lacked defining histological features and failed to express markers of differentiation.
The CNS HGNET-MN1 entity ( Figures 4G-4I ) consisted of circumscribed high-grade tumors containing a mixture of solid and pseudopapillary patterns. Dense pericellular hyalinization was frequently present in this group. Some had the typical pathology of the tumor termed astroblastoma (ABM) in the current WHO classification system, whereas others were harder to align with that diagnosis. The majority of tumors (16/23) from our current collection histologically diagnosed as ABM belonged to this molecular entity. Thus, we consider it unlikely that there is an additional true ''astroblastoma'' entity other than the MN1-altered entity outlined here.
The CNS HGNET-BCOR entity consisted of relatively compact tumors with a combination of spindle to oval cells. They often exhibited perivascular pseudorosettes, giving the tumors an ependymoma-like appearance ( Figures 4J-4L ). Tumors frequently demonstrated fibrillary processes, typical of glial differentiation, and only in rare instances exhibited true embryonal morphology.
Tumors from CNS HGNET-MN1 and CNS HGNET-BCOR entities frequently expressed GFAP, but neuronal antigen expression was either focal or absent. In comparison, mitotic counts Figure S3 and Table S3. were high for CNS NB-FOXR2 and CNS EFT-CIC tumors, but lower for the other two entities ( Figure S4C ).
Genetic Alterations Define New CNS Tumor Entities
For each of the four new CNS tumor entities, we next inspected copy-number profiles derived from DNA methylation arrays. Gain of chromosome arm 1q was characteristic for the CNS NB-FOXR2 entity (43/44, 98%; p < 0.001) ( Figure S5A ). Further broad aberrations included loss of 16q in CNS NB-FOXR2 (21/ 42, 50%) and CNS HGNET-MN1 (12/37, 32%), and gain of chromosome 8 in CNS NB-FOXR2 (14/44, 32%), CNS EFT-CIC (3/13, 23%), and CNS HGNET-MN1 (6/38, 16%) tumors. Most tumors from the CNS HGNET-BCOR entity displayed balanced copynumber profiles. We only detected high-level focal oncogene amplifications of MYC and CDK4, each in one CNS NB-FOXR2 sample, and EGFR and CDK4 in one CNS HGNET-MN1 sample (Table S4 ). Homozygous deletions of CDKN2A were found in two CNS HGNET-BCOR and one CNS HGNET-MN1 tumors.
In order to identify genetic alterations that underlie each of the four new, molecularly defined CNS tumor entities in greater detail, we performed genome-wide DNA and RNA sequencing of all cases with available fresh-frozen tissue (Table S4) . As outlined below, we found that each entity was characterized by a recurrent genetic alteration. CNS Neuroblastoma with FOXR2 Activation Genome-wide sequencing revealed complex inter-and intrachromosomal re-arrangements converging on forkhead box R2 (FOXR2) in 6/8 samples with available data, leading to increased FOXR2 gene expression levels in CNS NB-FOXR2 tumors compared with other CNS tumor entities ( Figures 5A-5C ). Three of the detected events resulted in fusion transcripts retaining the full coding sequence of FOXR2, with upstream non-coding exons forming a novel transcript variant fused to different fusion partners ( Figures S5B and  S5C ). These included JMJD1C as a result of a complex interchromosomal translocation involving chromosome 10, and LOC550643 and JPX as products of tandem duplications on chromosome X. These duplications were also detectable by characteristic copy-number changes in three samples without available sequencing data ( Figure S5D ). We further identified a recurrent deletion between full-length FOXR2 and MAGEH1 in two samples. Copy-number data indicated additional alterations targeting the FOXR2 locus in seven samples ( Figure S5D) , with a deletion reaching 500 kb upstream of FOXR2 as the most frequent event (4/46, 9%), potentially fusing FOXR2 to the MAGED2 gene.
Moreover, we identified a mitochondrial DNA insertion within USP51 that led to the formation of a novel FOXR2 promoter (Figure S5E) . Mitochondrial-nuclear genome fusions have been recently reported to occur frequently in cancer (Ju et al., 2015) , but this is the first example in which such an event induces oncogene expression. Since FOXR2 is not expressed in other CNS tumor types ( Figure 5C ) or normal brain tissues, these events are suggestive of FOXR2 activation facilitated by promoters of active genes ( Figure S5F ), thus instigating oncogenic activity (Rahrmann et al., 2013) . One exceptional tumor that did not show elevated gene expression of FOXR2 was the only one to harbor a focal amplification of MYC, resulting in upregulated MYC gene expression compared with FOXR2-activated tumors ( Figure S5F ). The FOXR2 homolog FOXR1 is recurrently activated in peripheral neuroblastoma counterparts by intrachromosomal deletion/fusion events, resulting in overexpression of fusion transcripts (Santo et al., 2012) .
CNS Ewing Sarcoma Family Tumor with CIC Alteration
In three tumors analyzed by RNA sequencing we detected an interchromosomal gene fusion between capicua transcriptional repressor (CIC, located on chromosome 19q13.2) and NUT midline carcinoma, family member 1 (NUTM1, located on chromosome 15q14) in two samples ( Figures 6A, 6B , and S6A), while the third harbored a frameshift deletion in CIC (exon6: c.902delC:p.S301fs). Both fusion events fused exon 16 of CIC in-frame to exon 4 of NUTM1, retaining the DNA-binding high mobility group (HMG) box domain of CIC. Using a CIC break-apart FISH probe, we identified CIC re-arrangements in 8/9 samples, including one of the tumors analyzed by RNA sequencing ( Figures 6B and S6B ), while the FISH-negative tumor carried the CIC frameshift deletion. Gene expression data indicated transcriptional upregulation of fusion partner NUTM1 in this group compared with all other samples (Figure 6C) . Consequently, those tumors showed strong reactivity when investigated for NUTM1 protein expression by immunohistochemistry, while no tumors from any other entity stained positive ( Figures 6B, S4A, and S4B ). On the basis of CIC fusions present in subgroups of pediatric primitive round cell sarcomas (Haidar et al., 2015) and their distinct transcriptional signature (Specht et al., 2014) , we analyzed CNS EFT-CIC tumors for similar gene expression patterns. As observed in peripheral EFT, among the genes specifically upregulated in this group were members of the ETS transcription factor family, including ETV1, ETV4, ETV5, FLI1, and ETS1 ( Figure S6C ). Oncogenic re-arrangements of NUTM1 are a defining genetic feature of NUT midline carcinomas (NMC), in most cases involving bromodomain-containing protein 4 (BRD4) (French, 2014) . We hypothesize a molecular mode of action of CIC-NUTM1 fusions in which specific CIC target genes are transcriptionally activated by the NUTM1 moiety via the recruitment of histone acetyl transferases, similar to a model of how BRD4-NUTM1 might block differentiation in NMC (French, 2014) . As this may lead to global hypoacetylation, these findings provide a rationale for testing the efficacy of epigenetically active drugs in this tumor entity.
CNS High-Grade Neuroepithelial Tumor with MN1 Alteration
We identified interchromosomal gene fusions between meningioma (disrupted in balanced translocation) 1 (MN1, 22q12.3) and BEN domain containing 2 (BEND2, Xp22.13) in three samples, and MN1 and CXXC-type zinc-finger protein 5 (CXXC5, 5q31.2) in one sample ( Figures 6D, 6E , and S6D) from RNA sequencing data of four tumors. Using an MN1 break-apart FISH probe, MN1 re-arrangement was confirmed in three of the tumors with RNA sequencing data and nine additional tumors from the CNS HGNET-MN1 entity ( Figures 6E and S6E ). High-level gene expression of the fusion partner BEND2 was observed specifically in CNS HGNET-MN1 tumors, while being absent in other CNS tumor types ( Figure 6F ). BEND2 immunohistochemistry failed to give reliable results due to non-specific staining with available antibodies. In the tumor with MN1-CXXC5 fusion, CXXC5 but not BEND2, was expressed at high levels (data not shown). A smaller set of five samples, including the tumor harboring the MN1-CXXC5 fusion, formed a distinctly separate cluster, while all three tumors harboring an MN1-BEND2 fusion were found in a larger homogenous cluster, potentially indicating differences in underlying biology depending on the MN1 fusion partner ( Figures 3A and S3A ). The gender bias was even more striking in the two separated clusters (male:female ratio: 2:32, p < 0.001; and 4:1, respectively). Fused to BEND2, the encoded chimeric protein combines the transactivating domains of MN1 and the two BEN domains in the C terminus of BEND2, which have been suggested to mediate protein-DNA and protein-protein interactions during chromatin organization and transcription (Abhiman et al., 2008) . In myeloid leukemia, frequently occurring MN1-TEL fusion proteins act as transcription factors with transforming activity both via targeting TEL binding sites (Buijs et al., 2000) and a dominant-negative effect on wild-type MN1 (van Wely et al., 2007) . See also Figure S5 and Table S4. samples ( Figures 6G, 6H , and S6F). The duplicated region in exon 15 of BCOR was identical with that of BCOR tandem duplications recently described in clear cell sarcomas of the kidney (Ueno-Yokohata et al., 2015) ( Figure S6G ). One additional tumor harbored an intragenic in-frame deletion in BCOR fusing the previous exon directly to the sequence duplicated in the other samples ( Figure S6F ), while two more tumors from that entity carried BCOR frameshift mutations. Duplications in BCOR were detected by targeted PCR in five additional tumors (Figures 6H and S6G) . Activation of the WNT signaling pathway as indicated by nuclear beta-catenin immunoreactivity was observed in 11/14 samples (79%) (Figures S4A and S4B ). Gene expression of BCOR was found at higher levels in CNS HGNET-BCOR tumors than in most other CNS tumor types ( Figure 6I ). High expression of altered BCOR transcripts in CNS HGNET-BCOR tumors suggests a mechanism different from BCOR loss-of-function mutations reported in other malignancies, such as medulloblastoma Pugh et al., 2012) .
Differential Pathway Activation in New CNS Tumor Entities
Array-based gene expression analyses of tumors from the four new entities (n = 34) identified many genes (range: 435-2,880) as significantly (adj. p < 0.001) differentially expressed between one versus the other three entities (Table S5) . Subsets of these genes, which frequently included transcription factors and potential drug targets, showed upregulated expression within the new entities ( Figures 7A and S7A ), suggesting activation of specific pathways or transcriptional networks ( Figure S7B ), and were also often not expressed in other CNS tumor entities (Figure 7B ). Gene-ranked pathway enrichment analysis (Reimand et al., 2011) of entity-specific genes relative to non-neoplastic brain tissues indicated several general and specific neuronal developmental processes being activated similarly in each of the four entities, but also identified deregulated processes and pathways more unique to one or more of the entities ( Figure S7C ; Tables S6A-S6D ). Number of cases 
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DISCUSSION
Our study demonstrates that the embryonal histology of CNSPNETs does not correspond to a homogeneous molecular class and suggests that a majority of tumors designated CNS-PNET represent morphological variants of other histologically and molecularly defined diagnostic entities. While a subset of tumors diagnosed as CNS-PNET were questionable or inaccurate diagnoses upon expert review, a high proportion of tumors demonstrated ambiguous small-cell morphology that was difficult to classify on histology alone, highlighting the diagnostic necessity of utilizing established molecular markers.
Our study also led to the identification of four new molecularly defined CNS tumor entities. The entity designated ''CNS neuroblastoma with FOXR2 activation'' consisted of a relatively pure population of CNS-PNET and was enriched for CNS-PNET variants CNS neuroblastoma and ganglioneuroblastoma. This entity therefore clarifies the molecular underpinnings of histopathological CNS-PNET variants into two primary entities, namely, ETMR (which accounts for the previously described ETANTR, ME, and EB) and CNS NB-FOXR2. We have further defined three additional molecular entities among pediatric CNS tumors, of which one entity, CNS HGNET-MN1, incorporates astroblastomas, while CNS EFT-CIC and CNS HGNET-BCOR represent novel entities displaying pathological overlap with CNS-PNET and other histological entities.
A minority of CNS-PNETs failed to classify into a specific subgroup, therefore representing a group we currently consider as ''CNS embryonal tumors, NOS.'' However, as international ini- See also Figure S7 and Tables S5 and S6. tiatives accumulate larger tumor series, our approach has potential to expand the molecular classification of malignant brain tumors, pushing the limits of what is recognized as a bona fide entity.
In conclusion, our findings reinforce the importance of incorporating molecular information into the next revision of the WHO classification of CNS tumors (Louis et al., 2014) and warrant a replacement of the term ''CNS-PNET'' with biologically specific designations. Our study provides an innovative framework for improving diagnostic accuracy and prognostication in malignant CNS tumors. The approach is amenable to retrospective analyses of patients treated with current regimens and will facilitate the design of more meaningful clinical trials for patients with malignant brain tumors.
EXPERIMENTAL PROCEDURES
Tumor samples and clinical data were collected at the DKFZ (Heidelberg, Germany) and at the St. Jude Children's Research Hospital (Memphis) in accordance with research ethics board approval from both institutes. Additional tumor samples and clinical data were provided by collaborating centers world-wide. Clinical patient details can be found in Tables S1A and S3 . An overview of all CNS-PNET and other CNS tumor samples included in various analyses is given within the Supplemental Experimental Procedures. Inclusion criteria for CNS-PNET samples comprised an institutional diagnosis of ''CNS-PNET'' (excluding medulloblastoma) and sufficient high-quality DNA for methylation profiling. Wherever possible, H&E-stained formalin-fixed paraffin-embedded (FFPE) sections from CNS-PNET and additional CNS tumor samples were reviewed by experienced neuropathologists (A.K., D.W.E., B.A.O., D.C.; n = 151; see Table S2 ).
DNA methylation profiling of CNS-PNET and reference samples was performed from both fresh-frozen and FFPE tissue using the Infinium HumanMethylation450 BeadChip Array (450k array) in accordance with the manufacturer's instructions (Illumina). For unsupervised hierarchical clustering of CNS-PNET and reference samples, we selected the 10,000 most variably methylated probes across the dataset. Copy-number variation (CNV) analysis from 450k methylation array data was performed using the conumee Bioconductor package (v.1.0.0). Scoring of focal amplifications and deletions and chromosomal gains and losses was performed by manual inspection of each profile.
Samples for which RNA of sufficient quantity and quality was available were analyzed on the Affymetrix GeneChip Human Genome U133 Plus (v.2.0) Array (Affymetrix). Sample library preparation, hybridization, and quality control were performed in accordance with the manufacturer's protocols.
Next-generation DNA and RNA sequencing was performed using Illumina technologies as previously described . In addition to automated detection of alterations, candidate genes and their 3 0 and 5 0 intergenic neighborhood were manually investigated using the Integrative Genomics Viewer (IGV) (Robinson et al., 2011) for any breakpoints. A detailed description of each analysis presented in this study can be found within the Supplemental Experimental Procedures.
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